Skip to main content

Table 2 The association between MMR immunophenotype with clinicopathological factors in I-type tumors, PB-type tumors, and the entire cohort respectively

From: Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma

  Intestinal type Pancreatobiliary type All
pMMR
(n = 50)
dMMR
(n = 13)
p pMMR
(n = 102)
dMMR
(n = 7)
p pMMR
(n = 152)
dMMR
(n = 20)
p
Age
 (Median, range) 66.5 (38.0–79.0) 67.0 (48.0–83.0) 0.905 67.0 (44.0–81.0) 62.0 (58.0–76.0) 0.669 67.0 (38.0–81.0) 65.5 (48.0–83.0) 0.635
Sex
 Women 26 (52.0) 8 (61.5) 0.539 46 (45.1) 4 (57.1) 0.538 72 (47.4) 12 (60.0) 0.289
 Men 24 (48.0) 5 (38.5)   56 (54.9) 3 (42.9)   80 (52.6) 8 (40.0)  
Tumor origin
 Duodenum 8 (16.0) 6 (46.2) 0.005     8 (5.3) 6 (28.6) 0.003
 Ampulla intestinal type 42 (84.0) 7 (53.8)      42 (27.6) 7 (35.0)  
 Ampulla pancreatobiliary type     17 (16.7) 2 (28.6) 0.860 17 (11.2) 2 (10.0)  
 Distal bile duct     44 (43.1) 1 (14.3)   44 (28.9) 1 (5.0)  
 Pancreas     41 (40.2) 4 (57.1)   41 (27.0) 4 (20.0)  
Tumor size mm
 (Median, range) 25.0 (5.0–60.0) 40.0 (13.0–90.0) 0.006 30.0 (9.0–70.0) 30.0 (5.0–35.0) 0.283 30.0 (5.0–70.0) 33.0 (5.0–90.0) 0.107
Differentiation grade
 Well-moderate 24 (48.0) 7 (53.8) 0.707 37 (36.3) 4 (57.1) 0.272 61 (40.1) 11 (55.0) 0.206
 Poor 26 (52.0) 6 (46.2)   65 (63.7) 3 (42.9)   91 (59.9) 9 (45.0)  
T-stage
 T1 4 (8.0) 0 0.736 2 (2.0) 0 0.966 6 (3.9) 0 0.420
 T2 9 (18.0) 2 (15.4)   11 (10.8) 1 (14.3)   20 (13.2) 3 (15.0)  
 T3 19 (38.0) 6 (46.2)   73 (71.6) 5 (71.4)   92 (60.5) 11 (55.0)  
 T4 18 (36.0) 5 (38.5)   16 (15.7) 1 (14.3)   34 (22.4) 6 (30.0)  
N-stage
 N0 24 (48.0) 9 (69.2) 0.348 26 (25.5) 6 (85.7) 0.002 50 (32.9) 15 (75.0) 0.002
 N1 17 (34.0) 2 (15.4)   44 (43.1) 1 (14.3)   61 (40.1) 3 (15.0)  
 N2 9 (18.0) 2 (15.4)   32 (31.4) 0   41 (27.0) 2 (10.0)  
Margins
 R0 13 (26.0) 4 (30.8) 0.730 6 (5.9) 0 0.511 19 (12.5) 4 (20.0) 0.356
 R1–Rx 37 (74.0) 9 (69.2)   96 (94.1) 7 (100.0)   133 (87.5) 16 (80.0)  
Perineural growth
 No 33 (66.0) 11 (84.6) 0.193 21 (20.6) 3 (42.9) 0.171 54 (35.5) 14 (70.0) 0.003
 Yes 17 (34.0) 2 (15.4)   81 (79.4) 4 (57.1)   98 (64.5) 6 (30.0)  
Invasion of lymphatic vessels
 No 18 (36.0) 11 (84.6) 0.002 29 (28.4) 5 (71.4) 0.018 47 (30.9) 16 (80.0) 0.000
 Yes 32 (64.0) 2 (15.4)   72 (71.6) 2 (28.6)   105 (69.1) 4 (20.0)  
Invasion of blood vessels
 No 45 (90.0) 13 (100.0) 0.235 67 (65.7) 5 (71.4) 0.757 112 (73.7) 18 (90.0) 0.111
 Yes 5 (10.0) 0   35 (3437) 2 (28.6)   40 (26.3) 2 (10.0)  
Growth in peripancreatic fat
 No 31 (62.0) 10 (76.9) 0.315 20 (19.6) 4 (57.1) 0.021 51 (33.6) 14 (70.0) 0.002
 Yes 19 (38.0) 3 (23.1)   82 (80.4) 3 (42.9)   101 (66.4) 6 (30.0)  
Adjuvant chemotherapy
 None 35 (70.0) 10 (76.9) 0.094 46 (45.1) 4 (57.1) 0.177 81 (53.3) 14 (70.0) 0.040
 5FU-analogue 5 (10.0) 0   8 (7.8) 0   13 (8.6) 0 (0.0)  
 Gemcitabine 7 (14.0) 0   43 (42.2) 2 (28.6)   50 (32.9) 2 (10.0)  
 Gemcitabine + capecitabine 0 1 (7.7)   3 (2.9) 0   3 (2.0) 1 (5.0)  
 Oxaliplatin + 5-FU analogue 2 (4.0) 2 (15.4)   1 (1.0) 0   3 (2.0) 2 (10.0)  
 Gemcitabine + oxaliplatin 1 (2.0) 0   1 (1.0) 1 (12.5)   2 (1.3) 1 (5.0)  
Immune cells
 CD3+ 206 (6–795) 246 (59–559) 0.156 129 (22–546) 44 (26–695) 0.092 148.5 (6–795) 227 (26–695) 0.471
 Missing 0 0   0 0   0 0  
 CD8+ 55 (2–180) 114 (2–180) 0.012 45 (4–175) 37 (1–200) 0.844 47.5 (2–180) 101.5 (1–200) 0.035
 Missing 1 0   3 0   4 0  
 FOXP3+ 33 (0–110) 40 (1–103) 0.497 26 (1–137) 15 (0–119) 0.420 27.5 (0–137) 38 (0–119) 0.560
 Missing 0 0   2 1   2 1  
 CD68+ 87 (29–350) 74 (19–182) 0.490 98 (25–230) 97 (36–230) 0.645 93 (25–350) 82 (19–229) 0.455
 Missing 0 0   1 1   1 1  
 CD163+ 130 (35–250) 120 (44–190) 0.755 140 (49–275) 162 (92–200) 0.241 136 (35–275) 131 (44–200) 0.885
 Missing 1 0   4 1   5 1  
 CD56+ 1 (0–9) 2 (0–23) 0.370 1 (0–12) 3 (0–33) 0.046 1 (0–12) 2 (0–33) 0.029
 Missing 0 0   0 0   0 0